Trial Profile
A Prospective, Open Label, Pilot Study Comparing the Use of Low-target Versus Conventional Target Advagraf Dosing in a Steroid-avoidance Immunosuppressive Protocol for de Novo Renal Transplant Recipients.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 08 Nov 2021
Price :
$35
*
At a glance
- Drugs Tacrolimus (Primary) ; Antithymocyte globulin; Basiliximab; Methylprednisolone sodium succinate; Mycophenolate mofetil; Mycophenolate sodium
- Indications Renal transplant rejection
- Focus Therapeutic Use
- 04 Feb 2020 Status changed from active, no longer recruiting to completed.
- 24 Sep 2019 Planned End Date changed from 1 Dec 2017 to 1 Sep 2022.
- 24 Sep 2019 Planned primary completion date changed from 1 Dec 2017 to 1 Sep 2022.